Changje Pharmaceutical Publishes Mid-Year Performance
Changje Pharmaceutical (00867) publishes its mid-year performance, with revenue growing 10.8% year-on-year to RMB 40.02 billion, and gross profit growing 7.2% year-on-year to RMB 28.92 billion. Durin
Changje Pharmaceutical (00867) publishes its mid-year performance, with revenue growing 10.8% year-on-year to RMB 40.02 billion, and gross profit growing 7.2% year-on-year to RMB 28.92 billion. During the period, net profit grew 3.1% year-on-year to RMB 9.315 billion, with shareholders' earnings expected to reach approximately RMB 9.41 billion, a growth of 3.38%. Basic earnings per share (EPS) stood at RMB 0.3892, and the company declared an interim dividend of RMB 0.1555 per share.